You are here: Industry Insights > Market News > Chinese Pharmaceutical Enterprises Listed on the Global 2000 of Forbes

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Riociguat(625115-55-1)

Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate

2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)

4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-

1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)

1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Chinese Pharmaceutical Enterprises Listed on the Global 2000 of Forbes

en-cphi.cnJune 09, 2017

Tag: china , Forbes

Favorites

Forbes has published the 2017 Global 2000 recently with the ranking based on a composite score from equally-weighted measures of revenue, profits, assets and market value.

The enterprises listed on the "Global 2000" this year are from 58 countries and regions, with total revenue of USD 35.3 trillion, profits of USD 2.5 trillion, assets of USD 169.1 trillion and market value of USD 48.8 trillion. The Industrial and Commercial Bank of China tops the list with annual revenue of USD 151.4 billion and market value of USD 3.4732 trillion.

Regarding the pharmaceutical industry, there are 63 companies listed, with total revenue of USD 1.4 trillion, profits of USD 139.7 billion, assets of USD 2.2 trillion, and total market value of USD 3.3 trillion.

J & J is still the top, with annual sales of USD 71.9 billion and market value of USD 338.6 billion, followed by Pfizer, Novartis, Roche, Sanofi, Bayer and Merck & Co, all among the top 100.

There are 6 Chinese pharmaceutical enterprises listed this year. Sinopharm Group ranks 581^st with annual sales of USD 38.9 billion, and CR Pharmaceutical ranks 1029^th with annual sales of USD 20.2 billion. Kangmei Pharmaceutical of which the market value has just exceeded RMB 100 billion lately surpasses Hengrui this time, ranking 1487^th, and Hengrui ranks 1497^th with market value of USD 18.7 billion and is the enterprise with the highest market value among the 6 Chinese pharmaceutical enterprises listed this time.

No.	Ranking	Company	Total revenue in 2016 (USD 100 million)	Profit in 2016 (USD 100 million)	Total assets (USD 100 million)	Market value (USD 100 million)
1	32	J & J	719	164	1412	3386
2	47	Pfizer	528	71	1716	2031
3	61	Novartis	485	67	1304	1932
4	79	Roche	513	97	756	2193
5	88	Sanofi	374	52	1104	1161
6	89	Bayer	518	50	901	944
7	100	Merck & Co	396	39	954	1733
8	131	Amgen	227	77	776	1203
9	134	Gilead	303	135	570	870
10	143	AbbVie	256	59	661	1045
11	149	Allergan	146	72	1290	801
12	176	AstraZeneca	230	37	625	752
13	188	McKesson	1965	20	579	305
14	194	GSK	376	12	730	998
15	221	Lilly	212	27	388	941
16	234	BMS	194	45	337	880
17	242	Abbott	209	14	550	757
18	281	Cardinal Health	1272	14	350	260
19	288	Merck	166	18	411	491
20	315	AmerisourceBergen	1483	13	339	190
21	346	Celgene	110	20	281	977
22	348	Takeda	159	12	355	369
23	372	Biogen	105	37	229	580
24	375	Novo Nordisk	166	56	138	882
25	485	Teva	219	3.37	929	324
26	520	Baxter	102	49	155	286
27	528	Astellas	121	19	159	280
28	562	Shire	116	3.42	670	513
29	578	Otsuka Pharmaceutical	110	8.52	227	251
30	581	Sinopharm Group	389	7.01	227	127
31	639	Mylan	111	4.8	347	212
32	806	CSL	64	13	81	439
33	839	Daiichi-Sankyo	89	5.5	170	155
34	986	Regeneron	49	8.8	70	404
35	1023	Sun Pharmaceutical	46	11	91	249
36	1029	CR Pharmaceutical	202	3.64	173	73
37	1047	Zoetis	49	8.21	76	258
38	1076	Quintiles IMS	69	1.15	212	187
39	1144	Actelion	25	7.07	21	305
40	1191	Grifols	45	6.03	107	168
41	1212	UCB	46	6.01	108	146
42	1219	Shionogi	31	8.52	55	174
43	1235	Aleck pharmaceutical	30	3.94	133	260
44	1248	Valeant	97	-24	435	33
45	1299	Medipal Holdings	282	2.96	135	37
46	1304	Eisai	49	5.07	89	149
47	1327	Illumina	24	4.64	43	252
48	1381	Alfresa Holdings	235	3.06	113	40
49	1428	Perrigo	56	-15	175	99
50	1487	Kangmei Pharmaceutical	32	4.96	79	134
51	1497	Hengrui Medicine	16	3.9	21	187
52	1548	Yunnan Baiyao	34	4.57	34	131
53	1584	Suzuken	201	2.44	106	32
54	1591	Novozymes	21	4.53	28	122
55	1594	ONO	22	4.44	106	32
56	1644	Vertex	17	-1.12	29	288
57	1645	Incyte	11	1.04	16	286
58	1716	Lupin	25	4.44	36	99
59	1766	Fosun Pharmaceutical	22	4.23	63	98
60	1901	Jazz	15	3.89	48	92
61	1901	Toho Holdings	118	1.99	56	16
62	1930	BMRN	11	-6.42	40	152
63	1962	Shanghai RAAS	3.26	2.31	20	145

Previous:ICH flooded the screen, China’s joining of ICH not officially recognized yet

Next:FDA requests removal of certain prescription opioid for risks related to abuse

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Innovent Biologics announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® .

Chinese Pharmaceutical Enterprises Listed on the Global 2000 of Forbes

Related News

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Macrogen Consortium win tender for National Bio Big Data Project

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

You may like
More>>

Chinese Pharmaceutical Enterprises Listed on the Global 2000 of Forbes

Related News

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

Macrogen Consortium win tender for National Bio Big Data Project

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

You may likeMore>>

You may like
More>>